MedTrace Logo

Anaesthetic Efficacy of 2% Mepivacaine Versus 4% Articaine With Symptomatic Irreversible Pulpitis

NCT04822415 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2021-08-02

No results posted yet for this study

Summary

The aim of this randomized, double-blinded, clinical trial was to assess the effect of 3.6 mL 2% mepivacaine hydrochloride with 1:100,000 epinephrine compared to 3.4 mL 4% articaine hydrochloride with 1:100,000 epinephrine on the success of the inferior alveolar nerve block for patients with symptomatic irreversible pulpitis in mandibular molars.

Conditions

  • Symptomatic Irreversible Pulpitis

Interventions

DRUG

Mepivacaine

IANB using 3.6 ml of 2% mepivacaine hydrochloride with 1:100,000 epinephrine.

DRUG

Articaine

IANB using 3.4 ml of 4% articaine hydrochloride with 1:100,000 epinephrine.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Randa ElBoghdadi, PhD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04822415 on ClinicalTrials.gov